AnalyzeDirect Bag AK, Kim H, Gao Y, Bolding M, Warren PP, Fathallah-Shaykh HM, Gurler D, Markert JM, Fiveash J, Beasley TM, Khawaja A, Friedman GK, Chapman PR, Nabors LB, Han X. Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. J Neurooncol. May 2015;122(3):585-593.
Publication Date
May 2015
How Analyze was Used
“The entire brain was segmented using an automated brain segmentation tool, Object Extractor,
which is supported by a commercial image processing software package, Analyze (version 11.0).”
Keywords
Atrophy
Bevacizumab
Brain
Cognition/drug effects
Control Groups
Glioma
Humans
Magnetic Resonance Imaging (MRI)
Neoplasm Recurrence, Local
Pilot Projects
Treatment Outcome
Author Affiliation(s)
Department of Radiology, The University of Alabama at Birmingham, Birmingham, US. (AKB, HK, MB, DG, PRC)
Department of Biomedical Informatics, Stony Brook University, New York, US. (YG)
Department of Neurology, The University of Alabama at Birmingham, FOT 1020; 510 20th Street South, Birmingham, AL, 35294, US. (PPW, HMFS, AK, LBN, XH)
Department of Neurosurgery, The University of Alabama at Birmingham, Birmingham, US. (JMM)
Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, US. (JF)
Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, US. (TMB)
Department of Hematology Oncology, The University of Alabama at Birmingham, Birmingham, US. (GKF)
ID# 2674
Tags: Atrophy, Bevacizumab, Brain, Cognition/drug effects, Control Groups, Glioma, Humans, Local Neoplasm Recurrence, Magnetic Resonance Imaging (MRI), Pilot Projects, Treatment Outcome